Search Results 621-630 of 17367 for alopecia
Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...
... alopecia or vitiligo). PRE-REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to pre-registration) (Must be >= 7 days after most recent ...
... alopecia prior to initiating protocol therapy. Bisphosphonate therapy and RANKL inhibitors are not considered anti-cancer therapy. Inadequate recovery from ...
alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of >30 Gray (Gy), they must ...
Find open clinical trials in the Mayo Clinic Division of Allergic Diseases.
Endometrial cancer, the most common uterine cancer, starts with abnormal cell growth in the endometrium. Significant risk factors include polycystic ovary ...
Page 1.
... alopecia or peripheral neuropathy. For Part F and H: concurrent treatment with trastuzumab emtansine (T-DM1) is not allowed. Exclusion Criteria: Have ...
Patients not recovered to Grade 1 or stabilized from the effects (excluding alopecia) of any prior therapy for their malignancies. Concurrent treatment with ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.